Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP. Morton MF, et al. Among authors: barrett td. J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. doi: 10.1124/jpet.107.124578. Epub 2007 Aug 7. J Pharmacol Exp Ther. 2007. PMID: 17684117
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
Rosen MD, Hack MD, Allison BD, Phuong VK, Woods CR, Morton MF, Prendergast CE, Barrett TD, Schubert C, Li L, Wu X, Wu J, Freedman JM, Shankley NP, Rabinowitz MH. Rosen MD, et al. Among authors: barrett td. Bioorg Med Chem. 2008 Apr 1;16(7):3917-25. doi: 10.1016/j.bmc.2008.01.059. Epub 2008 Feb 5. Bioorg Med Chem. 2008. PMID: 18289861
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP. Morton MF, et al. Among authors: barrett td. J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. Epub 2011 Apr 14. J Pharmacol Exp Ther. 2011. PMID: 21493750
Obestatin reduces food intake and suppresses body weight gain in rodents.
Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Lagaud GJ, et al. Among authors: barrett td. Biochem Biophys Res Commun. 2007 May 25;357(1):264-9. doi: 10.1016/j.bbrc.2007.03.138. Epub 2007 Mar 30. Biochem Biophys Res Commun. 2007. PMID: 17418097 Retracted.
SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.
Gomez L, Hack MD, McClure K, Sehon C, Huang L, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG. Gomez L, et al. Among authors: barrett td. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6493-8. doi: 10.1016/j.bmcl.2007.09.093. Epub 2007 Oct 1. Bioorg Med Chem Lett. 2007. PMID: 17933530
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.
Woods CR, Hack MD, Allison BD, Phuong VK, Rosen MD, Morton MF, Prendergast CE, Barrett TD, Shankley NP, Rabinowitz MH. Woods CR, et al. Among authors: barrett td. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6905-9. doi: 10.1016/j.bmcl.2007.09.087. Epub 2007 Sep 29. Bioorg Med Chem Lett. 2007. PMID: 18029172
44 results